Expression and function of ABCG2 and XIAP in glioblastomas
- 356 Downloads
Despite multimodal treatment that includes surgery, radiation and chemotherapy, virtually all glioblastomas (GBM) recur, indicating that these interventions are insufficient to eradicate all malignant cells. To identify potential new therapeutic targets in GBMs, we examined the expression and function of proteins that are associated with therapy resistance and cancer cell survival. We measured the expression of eight such proteins in 50 GBM samples by immunohistochemistry and analyzed patient survival. We report that GBM patients with high expression of ABCG2 (also called BCRP) or XIAP at the protein level had worse survival than those with low expression. The adjusted hazard ratio for ABCG2 was 2.35 and for XIAP was 2.65. Since glioma stem cells (GSCs) have been shown to be more resistant than bulk tumor cells to anti-cancer therapies and to express high levels of these proteins, we also sought to determine if ABCG2 and XIAP have functional roles in GSCs. We used small molecule inhibitors to treat patient-derived GBM tumorspheres in vitro and observed that inhibitors of ABCG2, Ko143 and fumitremorgin, significantly reduced self-renewal. These results suggest that ABCG2 and XIAP proteins may be useful indicators of patient survival and that inhibition of ABCG2 may be a promising therapeutic strategy in GBMs.
KeywordsGlioblastoma ABCG2 XIAP Ko143 Glioma stem cells
We thank Dr. Lee Lucas for her guidance with the statistical methods and Drs. Tom Gridley, Wendy Craig and Christine Lu-Emerson for their critical review of the manuscript. We also thank Jesse Hammer at the Jackson Laboratory’s Multimedia Department for his expert assistance in preparing the figures. We would like to acknowledge the Maine Medical Center BioBank, for their assistance in procuring biospecimens in accordance with IRB guidelines, and the Maine Medical Center Histology Core Facility (Grants P30GM103392 (R. Friesel, P.I.) and P30GM106391 (D. Wojchowski, P.I.), by the National Institute of General Medical Sciences) for their assistance with the immunohistochemistry staining.
This work was funded by unrestricted research grants from the Maine Medical Center Neuroscience Institute, the Northern New England Clinical Oncology Society, and the Schering-Plough Corporation (Grant ID XX-3903) to IFE and CB. This work was also supported by the Oliver S. and Jennie R. Donaldson Charitable Trust grant to KY. These sponsors had no involvement in study design, data collection, analysis or interpretation, manuscript writing, or the decision to submit the article for publication.
Compliance with ethical standards
Conflict of interest
The authors report no conflicts of interest beyond the direct research support detailed above.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the Maine Medical Center Institutional Review Board and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
- 8.Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, Goodell MA, Brenner MK (2004) A distinct “side population” of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 101:14228–14233. doi: 10.1073/pnas.04000671010400067101 CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Morfouace M, Cheepala S, Jackson S, Fukuda Y, Patel YT, Fatima S, Kawauchi D, Shelat AA, Stewart CF, Sorrentino BP, Schuetz JD, Roussel MF (2015) ABCG2 transporter expression impacts group 3 medulloblastoma response to chemotherapy. Cancer Res 75:3879–3889. doi: 10.1158/0008-5472.CAN-15-0030 CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H, Sorrentino BP (2001) The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 7:1028–1034CrossRefPubMedGoogle Scholar
- 16.Goodell MA, Rosenzweig M, Kim H, Marks DF, DeMaria M, Paradis G, Grupp SA, Sieff CA, Mulligan RC, Johnson RP (1997) Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med 3:1337–1345CrossRefPubMedGoogle Scholar
- 19.Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW, Holland EC (2009) PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell stem Cell 4:226–235. doi: 10.1016/j.stem.2009.01.007 CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Lee FA, Zee BC, Cheung FY, Kwong P, Chiang CL, Leung KC, Siu SW, Lee C, Lai M, Kwok C, Chong M, Jolivet J, Tung S (2014) Randomized phase II study of the X-linked inhibitor of apoptosis (XIAP) antisense AEG35156 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC). Am J Clin Oncol. doi: 10.1097/COC.0000000000000099 PubMedCentralGoogle Scholar
- 21.Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003. doi: 10.1056/NEJMoa043331 CrossRefPubMedGoogle Scholar
- 23.Allen JD, van Loevezijn A, Lakhai JM, van der Valk M, van Tellingen O, Reid G, Schellens JH, Koomen GJ, Schinkel AH (2002) Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther 1:417–425CrossRefPubMedGoogle Scholar
- 24.Nikolovska-Coleska Z, Xu L, Hu Z, Tomita Y, Li P, Roller PP, Wang R, Fang X, Guo R, Zhang M, Lippman ME, Yang D, Wang S (2004) Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. J Med Chem 47: 2430–2440. doi: 10.1021/jm030420+ CrossRefPubMedGoogle Scholar
- 27.Sandor S, Jordanidisz T, Schamberger A, Varady G, Erdei Z, Apati A, Sarkadi B, Orban TI (2016) Functional characterization of the ABCG2 5′ non-coding exon variants: stem cell specificity, translation efficiency and the influence of drug selection. Biochim Biophys Acta 1859:943–951. doi: 10.1016/j.bbagrm.2016.05.007 CrossRefPubMedGoogle Scholar
- 30.Kuppens IE, Witteveen EO, Jewell RC, Radema SA, Paul EM, Mangum SG, Beijnen JH, Voest EE, Schellens JH (2007) A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients. Clin Cancer Res 13:3276–3285. doi: 10.1158/1078-0432.CCR-06-2414 CrossRefPubMedGoogle Scholar
- 31.Kruijtzer CM, Beijnen JH, Rosing H, ten Bokkel Huinink WW, Schot M, Jewell RC, Paul EM, Schellens JH (2002) Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol 20:2943–2950CrossRefPubMedGoogle Scholar
- 32.Lagas JS, van Waterschoot RA, van Tilburg VA, Hillebrand MJ, Lankheet N, Rosing H, Beijnen JH, Schinkel AH (2009) Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment. Clin Cancer Res 15:2344–2351. doi: 10.1158/1078-0432.CCR-08-2253 CrossRefPubMedGoogle Scholar